A randomized multicenter study: safety and efficacy of mini‐pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1‐18 years with immune thrombocytopenia

BACKGROUNDBecause there is a global shortage of intravenous immunoglobulin, there is a need for new products to fill the gap.STUDY DESIGN AND METHODSThis was a multicenter, open‐label study investigating the safety and efficacy of a newly developed mini‐pool intravenous immunoglobulin G for children with immune thrombocytopenia. Seventy‐two patients ages 1 to 18 years with newly diagnosed (<1 month) immune thrombocytopenia who had platelet counts from 5 to 20 × 109/L with no serious bleeding were recruited from four centers in Egypt. Eligible patients were randomized into three groups 1:1:1. Group A (n = 24) received blood group–specific mini‐pool intravenous immunoglobulin in a dose equivalent to immunoglobulin 1 g/kg over 6 to 8 hours, Group B (n = 24) received standard intravenous immunoglobulin (approximately 1g/kg) as a single dose, and Group C (n = 24) did not receive any platelet‐enhancing therapy. Parents signed informed consent.RESULTSOf the patients who received mini‐pool intravenous immunoglobulin, 14 achieved a complete response (CR) (58.8%), and four had a response (16.6%). Of the patients who received intravenous immunoglobulin G, 16 achieved a complete response (66.6%), and four had a response (16.6%). In Group C, eight patients achieved a complete response (33.3%), and four had a response (16.6%). The median time to response was 8, 9, and 21 days in Group A, B, and C, respectively, which was significantly higher in Group C than Groups A and B (p < 0.001). Patients in Groups A and B reported 16 adverse drug reactions.CONCLUSIONMini‐pool intravenous immunoglobulin G was well tolerated, presented no safety issues, and was effective in the treatment of immune thrombocytopenia, with efficacy comparable to that of the standard intravenous immunoglobulin G group, and it was significantly more effective than no treatment.